Clinical Trial Update: First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b [Phase 1]

View source ↗

Summary

First-in-human dose expansion Phase 1 trial of XMT-1536 targeting NaPi2b in cancers likely to express the transporter, including platinum-resistant ovarian canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• XMT-1536

Snippet

Sponsor: Mersana Therapeutics | Conditions: Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma | Phase 1 | Status: COMPLETED